AU2016251236B2 - A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome - Google Patents

A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome Download PDF

Info

Publication number
AU2016251236B2
AU2016251236B2 AU2016251236A AU2016251236A AU2016251236B2 AU 2016251236 B2 AU2016251236 B2 AU 2016251236B2 AU 2016251236 A AU2016251236 A AU 2016251236A AU 2016251236 A AU2016251236 A AU 2016251236A AU 2016251236 B2 AU2016251236 B2 AU 2016251236B2
Authority
AU
Australia
Prior art keywords
cells
comp
vehicle
day
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016251236A
Other languages
English (en)
Other versions
AU2016251236A1 (en
Inventor
Rodger Anthony Allen
Francesca BARONE
William Anthony FAHY
Saba NAYAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of AU2016251236A1 publication Critical patent/AU2016251236A1/en
Application granted granted Critical
Publication of AU2016251236B2 publication Critical patent/AU2016251236B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2016251236A 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome Ceased AU2016251236B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506786.1 2015-04-21
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (2)

Publication Number Publication Date
AU2016251236A1 AU2016251236A1 (en) 2017-11-09
AU2016251236B2 true AU2016251236B2 (en) 2018-06-14

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016251236A Ceased AU2016251236B2 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome

Country Status (27)

Country Link
US (1) US10493074B2 (enExample)
EP (1) EP3285772B1 (enExample)
JP (1) JP6721606B2 (enExample)
KR (1) KR102627370B1 (enExample)
CN (1) CN107530344B (enExample)
AR (1) AR105552A1 (enExample)
AU (1) AU2016251236B2 (enExample)
BR (1) BR112017020591B8 (enExample)
CA (1) CA2981631C (enExample)
CL (1) CL2017002669A1 (enExample)
CO (1) CO2017010573A2 (enExample)
CY (1) CY1122572T1 (enExample)
DK (1) DK3285772T3 (enExample)
EA (1) EA032432B1 (enExample)
ES (1) ES2763335T3 (enExample)
GB (1) GB201506786D0 (enExample)
HR (1) HRP20192273T1 (enExample)
HU (1) HUE047162T2 (enExample)
IL (1) IL254766B (enExample)
LT (1) LT3285772T (enExample)
MX (1) MX2017013148A (enExample)
MY (1) MY192972A (enExample)
PL (1) PL3285772T3 (enExample)
PT (1) PT3285772T (enExample)
SG (1) SG11201707789YA (enExample)
SI (1) SI3285772T1 (enExample)
WO (1) WO2016170014A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032334A1 (en) * 2010-09-08 2012-03-15 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55546B1 (sr) * 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
PL2137186T3 (pl) * 2007-03-23 2016-09-30 Związki heterocykliczne i ich zastosowania
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012032334A1 (en) * 2010-09-08 2012-03-15 Ucb Pharma S.A. Quinoline and quinoxaline derivatives as kinase inhibitors

Also Published As

Publication number Publication date
US20180092921A1 (en) 2018-04-05
EP3285772A1 (en) 2018-02-28
JP2018513862A (ja) 2018-05-31
EP3285772B1 (en) 2019-10-02
MX2017013148A (es) 2018-02-21
BR112017020591B8 (pt) 2023-05-16
BR112017020591A2 (pt) 2018-07-03
BR112017020591B1 (pt) 2023-02-07
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
CN107530344A (zh) 2018-01-02
HRP20192273T1 (hr) 2020-03-06
KR102627370B1 (ko) 2024-01-18
US10493074B2 (en) 2019-12-03
SG11201707789YA (en) 2017-11-29
DK3285772T3 (da) 2020-01-13
EA201792318A1 (ru) 2018-05-31
LT3285772T (lt) 2020-01-10
ES2763335T3 (es) 2020-05-28
MY192972A (en) 2022-09-20
IL254766A0 (en) 2017-12-31
CL2017002669A1 (es) 2018-05-11
CA2981631C (en) 2023-02-21
PT3285772T (pt) 2020-01-14
GB201506786D0 (en) 2015-06-03
CY1122572T1 (el) 2021-01-27
AU2016251236A1 (en) 2017-11-09
IL254766B (en) 2020-05-31
CO2017010573A2 (es) 2018-03-09
SI3285772T1 (sl) 2020-02-28
AR105552A1 (es) 2017-10-18
PL3285772T3 (pl) 2020-05-18
CN107530344B (zh) 2020-03-17
KR20170140245A (ko) 2017-12-20
WO2016170014A1 (en) 2016-10-27
JP6721606B2 (ja) 2020-07-15
CA2981631A1 (en) 2016-10-27

Similar Documents

Publication Publication Date Title
Joy et al. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis
US9844535B2 (en) SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
US11660302B2 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
EP2969010B1 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
Liu et al. Activation of a7 nicotinic acetylcholine receptors prevents monosodium iodoacetate-induced osteoarthritis in rats
US20200179301A1 (en) Compositions and methods for treating muscular dystrophy and other disorders
AU2016251236B2 (en) A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome
EP3137089B1 (en) Use of ginsenoside m1 for treating lupus nephritis
EP3458058B1 (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
US20210382037A1 (en) Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agents
CN114748629A (zh) Ccl6/15/23在诊断过敏性气道炎症中的应用
AU2021360501A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
Ntali What''s new in clinical trials in lupus?
HK40008673B (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
HK40008673A (en) A pharmaceutical composition and the use thereof in the treatment of autoimmune diseases
HK1232801A1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired